Design, Synthesis and Structure-Activity Relationship Studies of Meridianin Derivatives as Novel JAK/STAT3 Signaling Inhibitors. 2022

Jian-Qiang Zhang, and Rui Li, and Xue-Yang Dong, and Na He, and Rui-Juan Yin, and Meng-Ke Yang, and Jie-Yu Liu, and Ri-Lei Yu, and Chen-Yang Zhao, and Tao Jiang
Key Laboratory of Marine Drugs, Ministry of Education, School of Medicine and Pharmacy, Ocean University of China, Qingdao 266003, China.

Hyperactivation of Janus kinase (JAK)/signal transducer and activator of transcription 3 (STAT3) signaling is an attractive therapeutic target for tumor therapy. Herein, forty-eight novel meridianin derivatives were designed and synthesized, and their antitumor activity was evaluated in vitro both for activity optimization and structure-activity relationship (SAR) study. The results indicated that most derivatives exhibited significantly improved antitumor activity, especially for compound 6e. The compound 6e contains an isothiouronium linked by an alkyl chain consisting of six carbon atoms with IC50 ranging from 1.11 to 2.80 μM on various cancer cell lines. Consistently, the 6e dose dependently induced the apoptosis of A549 and DU145 cells, in which STAT3 is constitutively active. Western blotting assays indicated that the phosphorylation levels of JAK1, JAK2 and STAT3 were inhibited by 6e at 5 μM without significant change in the total STAT3 level. Moreover, 6e also suppressed the expression of STAT3 downstream genes, including c-Myc, Cyclin D1 and Bcl-XL at 10 μM. An additional in vivo study revealed that 6e at the dose of 10 mg/kg could potently inhibit the DU145 xenograft tumor without obvious body weight loss. These results clearly indicate that 6e could be a potential antitumor agent by targeting the JAK/STAT3 signaling pathway.

UI MeSH Term Description Entries
D010766 Phosphorylation The introduction of a phosphoryl group into a compound through the formation of an ester bond between the compound and a phosphorus moiety. Phosphorylations
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000075242 Janus Kinase Inhibitors Agents that inhibit JANUS KINASES. JAK Inhibitor,Janus Kinase Inhibitor,JAK Inhibitors,Inhibitor, JAK,Inhibitor, Janus Kinase,Inhibitors, JAK,Inhibitors, Janus Kinase,Kinase Inhibitor, Janus,Kinase Inhibitors, Janus
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D015398 Signal Transduction The intracellular transfer of information (biological activation/inhibition) through a signal pathway. In each signal transduction system, an activation/inhibition signal from a biologically active molecule (hormone, neurotransmitter) is mediated via the coupling of a receptor/enzyme to a second messenger system or to an ion channel. Signal transduction plays an important role in activating cellular functions, cell differentiation, and cell proliferation. Examples of signal transduction systems are the GAMMA-AMINOBUTYRIC ACID-postsynaptic receptor-calcium ion channel system, the receptor-mediated T-cell activation pathway, and the receptor-mediated activation of phospholipases. Those coupled to membrane depolarization or intracellular release of calcium include the receptor-mediated activation of cytotoxic functions in granulocytes and the synaptic potentiation of protein kinase activation. Some signal transduction pathways may be part of larger signal transduction pathways; for example, protein kinase activation is part of the platelet activation signal pathway. Cell Signaling,Receptor-Mediated Signal Transduction,Signal Pathways,Receptor Mediated Signal Transduction,Signal Transduction Pathways,Signal Transduction Systems,Pathway, Signal,Pathway, Signal Transduction,Pathways, Signal,Pathways, Signal Transduction,Receptor-Mediated Signal Transductions,Signal Pathway,Signal Transduction Pathway,Signal Transduction System,Signal Transduction, Receptor-Mediated,Signal Transductions,Signal Transductions, Receptor-Mediated,System, Signal Transduction,Systems, Signal Transduction,Transduction, Signal,Transductions, Signal
D017209 Apoptosis A regulated cell death mechanism characterized by distinctive morphologic changes in the nucleus and cytoplasm, including the endonucleolytic cleavage of genomic DNA, at regularly spaced, internucleosomal sites, i.e., DNA FRAGMENTATION. It is genetically programmed and serves as a balance to mitosis in regulating the size of animal tissues and in mediating pathologic processes associated with tumor growth. Apoptosis, Extrinsic Pathway,Apoptosis, Intrinsic Pathway,Caspase-Dependent Apoptosis,Classic Apoptosis,Classical Apoptosis,Programmed Cell Death,Programmed Cell Death, Type I,Apoptoses, Extrinsic Pathway,Apoptoses, Intrinsic Pathway,Apoptosis, Caspase-Dependent,Apoptosis, Classic,Apoptosis, Classical,Caspase Dependent Apoptosis,Cell Death, Programmed,Classic Apoptoses,Extrinsic Pathway Apoptoses,Extrinsic Pathway Apoptosis,Intrinsic Pathway Apoptoses,Intrinsic Pathway Apoptosis
D045744 Cell Line, Tumor A cell line derived from cultured tumor cells. Tumor Cell Line,Cell Lines, Tumor,Line, Tumor Cell,Lines, Tumor Cell,Tumor Cell Lines
D049109 Cell Proliferation All of the processes involved in increasing CELL NUMBER including CELL DIVISION. Cell Growth in Number,Cellular Proliferation,Cell Multiplication,Cell Number Growth,Growth, Cell Number,Multiplication, Cell,Number Growth, Cell,Proliferation, Cell,Proliferation, Cellular
D050796 STAT3 Transcription Factor A signal transducer and activator of transcription that mediates cellular responses to INTERLEUKIN-6 family members. STAT3 is constitutively activated in a variety of TUMORS and is a major downstream transducer for the CYTOKINE RECEPTOR GP130. APRF Transcription Factor,Acute-Phase Response Factor,IL6-Response Factor,LIF-Response Factor,STAT3 Protein,STAT3a Transcription Factor,STAT3b Transcription Factor,Signal Transducer and Activator of Transcription 3,Stat3alpha Transcription Factor,Stat3beta Transcription Factor,Acute Phase Response Factor,IL6 Response Factor,LIF Response Factor,Response Factor, Acute-Phase,Transcription Factor, APRF,Transcription Factor, STAT3,Transcription Factor, STAT3a,Transcription Factor, STAT3b,Transcription Factor, Stat3alpha,Transcription Factor, Stat3beta
D053613 Janus Kinase 1 A Janus kinase subtype that is involved in signaling from a broad variety of CYTOKINE RECEPTORS. JAK-1 Protein Tyrosine Kinase,JAK1 Protein Tyrosine Kinase,Jak1 Kinase,JAK 1 Protein Tyrosine Kinase

Related Publications

Jian-Qiang Zhang, and Rui Li, and Xue-Yang Dong, and Na He, and Rui-Juan Yin, and Meng-Ke Yang, and Jie-Yu Liu, and Ri-Lei Yu, and Chen-Yang Zhao, and Tao Jiang
July 2023, Bioorganic & medicinal chemistry,
Jian-Qiang Zhang, and Rui Li, and Xue-Yang Dong, and Na He, and Rui-Juan Yin, and Meng-Ke Yang, and Jie-Yu Liu, and Ri-Lei Yu, and Chen-Yang Zhao, and Tao Jiang
July 2009, European journal of medicinal chemistry,
Jian-Qiang Zhang, and Rui Li, and Xue-Yang Dong, and Na He, and Rui-Juan Yin, and Meng-Ke Yang, and Jie-Yu Liu, and Ri-Lei Yu, and Chen-Yang Zhao, and Tao Jiang
May 2013, Journal of medicinal chemistry,
Jian-Qiang Zhang, and Rui Li, and Xue-Yang Dong, and Na He, and Rui-Juan Yin, and Meng-Ke Yang, and Jie-Yu Liu, and Ri-Lei Yu, and Chen-Yang Zhao, and Tao Jiang
August 2012, European journal of medicinal chemistry,
Jian-Qiang Zhang, and Rui Li, and Xue-Yang Dong, and Na He, and Rui-Juan Yin, and Meng-Ke Yang, and Jie-Yu Liu, and Ri-Lei Yu, and Chen-Yang Zhao, and Tao Jiang
May 2023, Bioorganic & medicinal chemistry letters,
Jian-Qiang Zhang, and Rui Li, and Xue-Yang Dong, and Na He, and Rui-Juan Yin, and Meng-Ke Yang, and Jie-Yu Liu, and Ri-Lei Yu, and Chen-Yang Zhao, and Tao Jiang
March 2011, Archiv der Pharmazie,
Jian-Qiang Zhang, and Rui Li, and Xue-Yang Dong, and Na He, and Rui-Juan Yin, and Meng-Ke Yang, and Jie-Yu Liu, and Ri-Lei Yu, and Chen-Yang Zhao, and Tao Jiang
January 2015, European journal of medicinal chemistry,
Jian-Qiang Zhang, and Rui Li, and Xue-Yang Dong, and Na He, and Rui-Juan Yin, and Meng-Ke Yang, and Jie-Yu Liu, and Ri-Lei Yu, and Chen-Yang Zhao, and Tao Jiang
February 2018, Journal of medicinal chemistry,
Jian-Qiang Zhang, and Rui Li, and Xue-Yang Dong, and Na He, and Rui-Juan Yin, and Meng-Ke Yang, and Jie-Yu Liu, and Ri-Lei Yu, and Chen-Yang Zhao, and Tao Jiang
June 2019, Bioorganic & medicinal chemistry letters,
Jian-Qiang Zhang, and Rui Li, and Xue-Yang Dong, and Na He, and Rui-Juan Yin, and Meng-Ke Yang, and Jie-Yu Liu, and Ri-Lei Yu, and Chen-Yang Zhao, and Tao Jiang
June 2014, Journal of medicinal chemistry,
Copied contents to your clipboard!